LB Pharmaceuticals Inc Common Stock(LBRX)Earnings, Financials & Key Ratios
LBRX•NASDAQ
$32.64
Price updated Jun 30, 2026
AboutClinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.Show more
- Revenue$0
- EBITDA-$30M+53.5%
- Net Income-$25M+60.1%
- EPS (Diluted)-1.00+94.4%
- ROE-24.38%
LBRX Price & Volume
LB Pharmaceuticals Inc Common Stock (LBRX) stock price & volume — 10-year historical chart
Loading chart...
Accelerated Clinical Spending Drives Significant Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNeutral: While the $320.7 million cash reserve provides a strong buffer
Growth:Contracting
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial execution burn
Key Thesis Takeaways
- LB Pharmaceuticals is currently in a high-intensity development phase, characterized by a zero-revenue profile and escalating R&D expenditures that reached $14.6 million in 2026Q1.
- While the company has successfully bolstered its equity base to $378.7 million, the widening quarterly operating loss of $22.1 million necessitates careful monitoring of the firm's long-term capital runway.
- Investors should weigh the potential of the neuropsychiatric pipeline against the persistent cash consumption and the inherent risks associated with late-stage clinical trial execution.
Verdict Logic
the accelerating quarterly burn rate of $23.3 million warrants caution until the company demonstrates a clear path toward clinical milestones or revenue generation.
LBRX Growth Metrics
LB Pharmaceuticals Inc Common Stock (LBRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-64.15%
5 Years-64.15%
3 Years-81.08%
Last Year-18.38%
LBRX Recent Earnings
LB Pharmaceuticals Inc Common Stock (LBRX) EPS & revenue vs analyst estimates — last 3 quarters
●Beat EPS 1/3 qtrs (33%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.67+10.7%
$0.75
Rev
—
—
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.45+0.0%
$0.45
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.61-7.0%
$0.57
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.67vs $0.75+10.7% | — |
| Q2 2026 | Mar 26, 2026 | $0.45vs $0.45+0.0% | — |
| Q4 2025 | Nov 6, 2025 | $0.61vs $0.57-7.0% | — |
Based on last 3 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for LB Pharmaceuticals Inc Common Stock (LBRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $32.64 | $936.01M | -32.64 | — | — | -24.38% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $4.34 | $17.12M | -0.17 | — | — | -381.01% | — | |
| $23.14 | $1.71B | 7.01 | 18.52% | 118.91% | 47.59% | — | |
| $25.20 | $4.31B | 11.00 | 11.87% | 34.3% | 35.65% | — | |
| $241.12 | $12.41B | -65.52 | 65.55% | -26.59% | -260.01% | — |
Compare LBRX vs Peers
LB Pharmaceuticals Inc Common Stock (LBRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when LBRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LBRX Frequently Asked Questions
LB Pharmaceuticals Inc Common Stock (LBRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is LBRX profitable?
LB Pharmaceuticals Inc Common Stock (LBRX) reported a net loss of $39.2M for fiscal year 2025.
Dividend & Returns
What is LBRX's return on equity?
LB Pharmaceuticals Inc Common Stock (LBRX) has a return on equity (ROE) of -24.4%. Negative ROE indicates the company is unprofitable.
What is LB Pharmaceuticals Inc Common Stock's free cash flow?
LB Pharmaceuticals Inc Common Stock (LBRX) had negative free cash flow of $51.7M in fiscal year 2025, likely due to heavy capital investments.